Press Release

Press Release - Q2FY27 - Revenue 15.6bn +20% y-y; EBITDA 3.38bn +21% y-y (margin 22%); PAT 1.82bn +39% y-y - North America revenue share 72% (Q2FY26: 76%), Europe 16% (Q2FY26: 12%) - Revenue mix: Finished dosages 73%, API 13%, PFI 10%, Peptides CDMO 3% - ROCE steady at 17.6% in Q2FY27, same as FY26 - Net cash position improved to ₹8,280 mn from net debt ₹1,012 mn in Q1FY27 - Chairman: Cost pressures persist due to West Asia tensions; working with customers on lagged management - Filed 3 potential first-to-file ANDAs; focus on complex generics and peptide CDMO - US FDA audit at Gagillapur site concluded constructively; observations manageable with corrective actions